Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved LUMAKRAS® (sotorasib) in ...
Amgen’s Lumakras and AstraZeneca’s Calquence are both in line to expand their respective oncology reaches with new FDA ...
The Phase III CodeBreaK 300 study returned disappointing overall survival data for Lumakras plus Vectibix in metastatic ...
Friday announced that the U.S. Food and Drug Administration has approved its Lumakras plus Vectibix combination ...
Amgen (AMGN) announced that the U.S. FDA has approved Lumakras in combination with Vectibix for the treatment of adult patients with KRAS ...
The CodeBreaK 300 results demonstrated that Lumakras 960 mg daily plus Vectibix (n=53) showed an improved median ...
Lumakras, primarily known for lung cancer treatment, became the first FDA-approved KRASG12C inhibitor in 2021 for non-small ...
Pivotal Study Demonstrated the Combination More Than Doubled Progression-Free Survival Compared to Investigated SOC THOUSAND OAKS, Calif., Jan. 17, 2025 /PRNewswire/ ...
Medpage Today on MSN22h
'CDC Must Be Investigated'; David Lynch, Bob Uecker Die; Nasal Epinephrine Warning"The CDC must be investigated for its misuse of PEPFAR funds," said Sen. Jim Risch (R-Idaho), following a report that funds ...
The FDA approved two oncology regimens on Jan. 16.One is for a subset of patients with colorectal cancer and the other for ...
More debate about whether the lowest-risk prostate cancers should even be called "cancer." (Harvard Health Publishing) Four ...
Revision Skincare®, a leader in professional skincare innovation, announces the launch of DermProtect Barrier Defensetm, an intensive moisturizer that sets a new standard in barrier repair and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback